Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

OMID FATEMI

Allopathic & Osteopathic Physicians Internal Medicine Interventional Cardiology

NPI
1326293143
CMS profile
743090
Location
VENTURA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$13,298.00

139 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 139 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

OMID FATEMI

NPI 1326293143 · CMS profile ID 743090

Allopathic & Osteopathic Physicians / Internal Medicine / Interventional Cardiology

VENTURA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 139 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1326293143?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
OMID FATEMI, NPI 1326293143, CMS profile ID 743090. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 139 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1326293143?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). OMID FATEMI, NPI 1326293143, CMS profile ID 743090. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 139 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1326293143?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
OMID FATEMI, NPI 1326293143, CMS profile ID 743090, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 139 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1326293143?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

139 matching records · $13,298.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 139 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 139.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boston Scientific Corporation $4.3709/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022148915 CMS
Edwards Lifesciences Corporation $592.8109/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023079035 CMS
Edwards Lifesciences Corporation $139.0609/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023078989 CMS
Boston Scientific Corporation $8.7109/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022148849 CMS
Edwards Lifesciences Corporation $13.4008/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023078977 CMS
Novartis Pharmaceuticals Corporation $27.2808/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991613753 CMS
Baxter Healthcare $40.3308/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996989645 CMS
Edwards Lifesciences Corporation $9.2808/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023078981 CMS
E.R. Squibb & Sons, L.L.C. $16.4408/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016212787 CMS
Abbott Laboratories $23.6408/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017995643 CMS
Boston Scientific Corporation $5.2008/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022148968 CMS
Edwards Lifesciences Corporation $9.3008/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023078979 CMS
Edwards Lifesciences Corporation $11.2808/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023078985 CMS
Boston Scientific Corporation $4.2808/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022148887 CMS
Edwards Lifesciences Corporation $15.2608/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023078983 CMS
Boston Scientific Corporation $5.5507/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022148715 CMS
Edwards Lifesciences Corporation $154.0307/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023078987 CMS
Abbott Laboratories $129.2407/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019335545 CMS
Boston Scientific Corporation $4.3307/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022148901 CMS
Edwards Lifesciences Corporation $12.1507/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023078929 CMS
Boston Scientific Corporation $5.2007/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022148955 CMS
Edwards Lifesciences Corporation $6.1207/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023078993 CMS
Edwards Lifesciences Corporation $29.1607/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023078927 CMS
Edwards Lifesciences Corporation $8.4506/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023078921 CMS
Boston Scientific Corporation $8.2506/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022101639 CMS
Edwards Lifesciences Corporation $11.5006/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023078923 CMS
Baxter Healthcare $16.0706/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996989641 CMS
Boston Scientific Corporation $9.2006/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022148863 CMS
Edwards Lifesciences Corporation $400.8606/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023078917 CMS
Boston Scientific Corporation $6.5906/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021811519 CMS
Edwards Lifesciences Corporation $164.3906/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023078919 CMS
Edwards Lifesciences Corporation $1,200.0006/08/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023078905 CMS
ABIOMED $138.4206/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044826729 CMS
Edwards Lifesciences Corporation $7.8906/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023078913 CMS
Edwards Lifesciences Corporation $165.4206/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023078915 CMS
Abbott Laboratories $32.8705/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019166429 CMS
Abbott Laboratories $24.6205/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019166447 CMS
Boston Scientific Corporation $17.2605/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022148751 CMS
Boston Scientific Corporation $6.8205/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022110291 CMS
Edwards Lifesciences Corporation $8.2505/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023078909 CMS
Novartis Pharmaceuticals Corporation $25.7605/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991613729 CMS
Boston Scientific Corporation $5.4305/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022148711 CMS
Boston Scientific Corporation $19.6305/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022148753 CMS
Edwards Lifesciences Corporation $7.9205/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023078911 CMS
Boston Scientific Corporation $6.6705/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022101599 CMS
Medtronic, Inc. $75.6405/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019514003 CMS
E.R. Squibb & Sons, L.L.C. $16.3005/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016212707 CMS
Edwards Lifesciences Corporation $4.5004/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023078895 CMS
iRhythm Technologies, Inc. $26.0204/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059036661 CMS
Boston Scientific Corporation $4.3704/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022101643 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,268.26 71
PY2020 $1,093.16 45
PY2021 $2,724.74 97
PY2022 $7,537.58 139
PY2023 $13,298.00 139
PY2024 $9,749.61 107
PY2025 $28,607.48 148

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $294,817.85 15
PY2024 Principal investigator $463,717.03 19
PY2023 Principal investigator $287,483.21 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

15 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $21,338.00 12/19/2025 Non-covered Recipient Entity
Crdlgy Associates Medcl Group-Ventura
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175181955
Principal investigator 1 Janssen Research & Development, LLC $9,754.00 12/12/2025 Non-covered Recipient Entity
Crdlgy Associates Medcl Group-Ventura
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175181995
Principal investigator 1 Janssen Research & Development, LLC $13,392.00 11/19/2025 Non-covered Recipient Entity
Crdlgy Associates Medcl Group-Ventura
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175181964
Principal investigator 1 Janssen Research & Development, LLC $24,240.00 11/07/2025 Non-covered Recipient Entity
Crdlgy Associates Medcl Group-Ventura
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175181948
Principal investigator 1 Novartis Pharmaceuticals Corporation $28,929.85 10/27/2025 Non-covered Recipient Entity
CARDIOLOGY ASSOCIATES MEDICAL GROUP, INC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190302565
Principal investigator 1 Janssen Research & Development, LLC $20,556.00 09/19/2025 Non-covered Recipient Entity
Crdlgy Associates Medcl Group-Ventura
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175182004
Principal investigator 1 Janssen Research & Development, LLC $21,080.00 08/25/2025 Non-covered Recipient Entity
Crdlgy Associates Medcl Group-Ventura
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175181971
Principal investigator 1 Janssen Research & Development, LLC $3,574.00 07/23/2025 Non-covered Recipient Entity
Crdlgy Associates Medcl Group-Ventura
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175182033
Principal investigator 1 Janssen Research & Development, LLC $13,422.00 06/23/2025 Non-covered Recipient Entity
Crdlgy Associates Medcl Group-Ventura
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175181940
Principal investigator 1 Janssen Research & Development, LLC $17,924.00 06/20/2025 Non-covered Recipient Entity
Crdlgy Associates Medcl Group-Ventura
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175182010
Principal investigator 1 Janssen Research & Development, LLC $15,378.00 05/21/2025 Non-covered Recipient Entity
Crdlgy Associates Medcl Group-Ventura
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175181988
Principal investigator 1 Janssen Research & Development, LLC $25,194.00 04/23/2025 Non-covered Recipient Entity
Crdlgy Associates Medcl Group-Ventura
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175181979
Principal investigator 1 Janssen Research & Development, LLC $24,173.00 03/21/2025 Non-covered Recipient Entity
Crdlgy Associates Medcl Group-Ventura
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175182039
Principal investigator 1 Janssen Research & Development, LLC $24,536.00 02/19/2025 Non-covered Recipient Entity
Crdlgy Associates Medcl Group-Ventura
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175182019
Principal investigator 1 Janssen Research & Development, LLC $31,327.00 01/22/2025 Non-covered Recipient Entity
Crdlgy Associates Medcl Group-Ventura
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175182026